{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:08:35Z","timestamp":1781521715075,"version":"3.54.1"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.steroids.2014.07.012","type":"journal-article","created":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T02:50:36Z","timestamp":1406861436000},"page":"82-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Ospemifene: A first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy"],"prefix":"10.1016","volume":"90","author":[{"given":"Michael W.","family":"DeGregorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Zerbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory T.","family":"Wurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2014.07.012_b0005","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2014.07.012_b0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/jm020449y","article-title":"Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions","volume":"46","author":"Jordan","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.steroids.2014.07.012_b0015","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/jm020450x","article-title":"Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents","volume":"46","author":"Jordan","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.steroids.2014.07.012_b0020","series-title":"Development of therapeutic agents handbook","first-page":"1019","article-title":"Evolution of selective estrogen and androgen receptor modulators: status of current therapy and new drug development","author":"Wurz","year":"2012"},{"key":"10.1016\/j.steroids.2014.07.012_b0025","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/jnci\/91.19.1654","article-title":"Tamoxifen therapy for breast cancer and endometrial cancer risk","volume":"91","author":"Bernstein","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2014.07.012_b0030","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/13697130500117946","article-title":"Urogenital effects of selective estrogen receptor modulators: a systematic review","volume":"8","author":"Albertazzi","year":"2005","journal-title":"Climacteric"},{"key":"10.1016\/j.steroids.2014.07.012_b0035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/A:1006002324995","article-title":"Intrinsic reactivity of tamoxifen and toremifene metabolites with DNA","volume":"50","author":"Hellmann-Blumberg","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2014.07.012_b0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1006311214152","article-title":"Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene","volume":"60","author":"Hellmann-Blumberg","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2014.07.012_b0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1005891506092","article-title":"A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group","volume":"45","author":"Gershanovich","year":"1997","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2014.07.012_b0050","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.1995.13.10.2556","article-title":"Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer","volume":"13","author":"Hayes","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2014.07.012_b0055","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1006440802709","article-title":"Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer","volume":"65","author":"Milla-Santos","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2014.07.012_b0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1023\/A:1006250213357","article-title":"Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer","volume":"56","author":"Pyrhonen","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2014.07.012_b0065","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1997.375","article-title":"Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the \u2018nordic\u2019 phase III study","volume":"76","author":"Pyrhonen","year":"1997","journal-title":"Br J Cancer"},{"issue":"Suppl. 6","key":"10.1016\/j.steroids.2014.07.012_b0070","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0959-8049(02)00279-4","article-title":"Tamoxifen versus toremifene in the adjuvant treatment of breast cancer","volume":"38","author":"Holli","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.steroids.2014.07.012_b0075","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1200\/JCO.2000.18.20.3487","article-title":"Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group","volume":"18","author":"Holli","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2014.07.012_b0080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.breast.2005.09.007","article-title":"Toremifene: an evaluation of its safety profile","volume":"15","author":"Harvey","year":"2006","journal-title":"Breast"},{"key":"10.1016\/j.steroids.2014.07.012_b0085","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2014.07.012_b0090","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.07.012_b0095","first-page":"1446","article-title":"Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer","volume":"43","author":"Jordan","year":"1983","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2014.07.012_b0100","unstructured":"Osphena\u2122 (ospemifene) prescribing information. Shionogi Inc., Florham Park, New Jersey, 2013."},{"key":"10.1016\/j.steroids.2014.07.012_b0105","series-title":"Painful sex associated with menopause: interpreting FDA warnings when choosing a treatment for dyspareunia","author":"DeGregorio","year":"2014"},{"key":"10.1016\/j.steroids.2014.07.012_b0110","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1743-6109.2009.01335.x","article-title":"Prevalence and impact of vaginal symptoms among postmenopausal women","volume":"6","author":"Santoro","year":"2009","journal-title":"J Sex Med"},{"issue":"Suppl. 4","key":"10.1016\/j.steroids.2014.07.012_b0115","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3949\/ccjm.75.Suppl_4.S17","article-title":"Update on nonhormonal approaches to menopausal management","volume":"75","author":"Jenkins","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.steroids.2014.07.012_b0120","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/jama.2010.1500","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women","volume":"304","author":"Chlebowski","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.07.012_b0125","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-157-2-201207170-00466","article-title":"Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations","volume":"157","author":"Nelson","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.steroids.2014.07.012_b0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.07.012_b0135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrendo.2013.17","article-title":"Postmenopausal hormone therapy: risks and benefits","volume":"9","author":"Rozenberg","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"20","key":"10.1016\/j.steroids.2014.07.012_b0140","first-page":"888","article-title":"Management of symptomatic vulvovaginal atrophy, position statement of The North American Menopause Society","volume":"2013","author":"NAMS","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.07.012_b0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0378-5122(02)00206-2","article-title":"Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women","volume":"43","author":"Voipio","year":"2002","journal-title":"Maturitas"},{"key":"10.1016\/j.steroids.2014.07.012_b0150","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jsbmb.2013.04.004","article-title":"Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause","volume":"138","author":"Unkila","year":"2013","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2014.07.012_b0155","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1124\/pr.58.4.8","article-title":"International Union of Pharmacology. LXIV. Estrogen receptors","volume":"58","author":"Dahlman-Wright","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.steroids.2014.07.012_b0160","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00026.2006","article-title":"Estrogen receptors: how do they signal and what are their targets","volume":"87","author":"Heldring","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.steroids.2014.07.012_b0165","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2174\/092986707780598023","article-title":"Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs)","volume":"14","author":"Musa","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.steroids.2014.07.012_b0170","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/39645","article-title":"Molecular basis of agonism and antagonism in the oestrogen receptor","volume":"389","author":"Brzozowski","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.steroids.2014.07.012_b0175","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1126\/science.280.5370.1747","article-title":"Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors","volume":"280","author":"Feng","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.steroids.2014.07.012_b0180","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1126\/science.1068537","article-title":"Molecular determinants for the tissue specificity of SERMs","volume":"295","author":"Shang","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.steroids.2014.07.012_b0185","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1204729","article-title":"Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells","volume":"20","author":"Marquez","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.steroids.2014.07.012_b0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0303-7207(01)00526-3","article-title":"Differential cellular localization of estrogen receptor alpha in uterine and mammary cells","volume":"181","author":"Monje","year":"2001","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.steroids.2014.07.012_b0195","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1126\/science.1106943","article-title":"A transmembrane intracellular estrogen receptor mediates rapid cell signaling","volume":"307","author":"Revankar","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.steroids.2014.07.012_b0200","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1186\/bcr959","article-title":"Membrane estrogen receptor-alpha levels predict estrogen-induced ERK1\/2 activation in MCF-7 cells","volume":"7","author":"Zivadinovic","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.steroids.2014.07.012_b0205","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1211\/0022357022089","article-title":"Non-genomic effects of tamoxifen on the activation of membrane-bound guanylate cyclase GC-A","volume":"55","author":"Chen","year":"2003","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.steroids.2014.07.012_b0210","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1677\/jme.1.01784","article-title":"Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells","volume":"35","author":"Horner-Glister","year":"2005","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.steroids.2014.07.012_b0215","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/jcp.22461","article-title":"Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor alpha and beta","volume":"226","author":"Rossi","year":"2011","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.steroids.2014.07.012_b0220","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1200\/JCO.1992.10.6.990","article-title":"Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors","volume":"10","author":"Wiebe","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2014.07.012_b0225","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1992.10.2.304","article-title":"Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients","volume":"10","author":"Osborne","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2014.07.012_b0230","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/oxfordjournals.annonc.a058251","article-title":"Towards a molecular basis for tamoxifen resistance in breast cancer","volume":"3","author":"Johnston","year":"1992","journal-title":"Ann Oncol"},{"key":"10.1016\/j.steroids.2014.07.012_b0235","unstructured":"DeGregorio M, Wiebe V, Kangas L, H\u00e4rk\u00f6nen P, V\u00e4\u00e4n\u00e4nen K, Laine A. Triphenylethylenes Compositions (United States Patent). USPTO, Patent number 5,912,273, June 15, 1999."},{"key":"10.1016\/j.steroids.2014.07.012_b0240","series-title":"Sex steroids and bone","first-page":"71","article-title":"Effects of estrogen on growth factors in bone","author":"Bonewald","year":"1994"},{"key":"10.1016\/j.steroids.2014.07.012_b0245","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/(SICI)1097-4644(19990615)73:4<500::AID-JCB8>3.0.CO;2-E","article-title":"Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture","volume":"73","author":"Qu","year":"1999","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.steroids.2014.07.012_b0250","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/sj.bjp.0707232","article-title":"Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro","volume":"151","author":"Michael","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.steroids.2014.07.012_b0255","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.mce.2008.03.005","article-title":"Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells","volume":"289","author":"Kallio","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.steroids.2014.07.012_b0260","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1210\/endo.141.2.7342","article-title":"Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats","volume":"141","author":"Qu","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2014.07.012_b0265","first-page":"27","article-title":"Effects of the selective estrogen receptor modulator ospemifene on bone in rats","volume":"46","author":"Kangas","year":"2014","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.steroids.2014.07.012_b0270","first-page":"3925","article-title":"Mechanism of lower genotoxicity of toremifene compared with tamoxifen","volume":"61","author":"Shibutani","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2014.07.012_b0275","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1742-7843.2008.00235.x","article-title":"Pharmacologic effects of ospemifene in rhesus macaques: a pilot study","volume":"102","author":"Wurz","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.steroids.2014.07.012_b0280","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0960-0760(01)00066-8","article-title":"In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer","volume":"77","author":"Taras","year":"2001","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2014.07.012_b0285","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.steroids.2013.09.003","article-title":"Tissue selectivity of ospemifene: pharmacologic profile and clinical implications","volume":"78","author":"Kangas","year":"2013","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2014.07.012_b0290","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0034-1367032","article-title":"Effects of ospemifene on breast tissue morphology and proliferation: a comparative study versus other selective estrogen receptor modulators in ovariectomized rats","volume":"46","author":"Kangas","year":"2014","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.steroids.2014.07.012_b0295","first-page":"605","article-title":"Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast","volume":"5","author":"Soe","year":"2013","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.steroids.2014.07.012_b0300","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.maturitas.2012.12.002","article-title":"Ospemifene, vulvovaginal atrophy, and breast cancer","volume":"74","author":"Wurz","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.steroids.2014.07.012_b0305","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jsbmb.2005.06.027","article-title":"Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice","volume":"97","author":"Wurz","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2014.07.012_b0310","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0002-9440(10)63568-7","article-title":"Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases","volume":"163","author":"Lin","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.steroids.2014.07.012_b0315","doi-asserted-by":"crossref","first-page":"R881","DOI":"10.1186\/bcr1317","article-title":"Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ","volume":"7","author":"Namba","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.steroids.2014.07.012_b0320","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1128\/MCB.12.3.954","article-title":"Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease","volume":"12","author":"Guy","year":"1992","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.steroids.2014.07.012_b0325","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/gme.0b013e318223e82a","article-title":"Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model","volume":"19","author":"Burich","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.07.012_b0330","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/gme.0b013e3181c4f1d6","article-title":"Endometrial safety: a key hurdle for selective estrogen receptor modulators in development","volume":"17","author":"Pinkerton","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.07.012_b0335","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jsbmb.2003.11.009","article-title":"Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus","volume":"88","author":"Zheng","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2014.07.012_b0340","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00042192-200512020-00015","article-title":"Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women","volume":"12","author":"Komi","year":"2005","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.07.012_b0345","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.GME.0000063566.84134.98","article-title":"Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women","volume":"10","author":"Ylikorkala","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.07.012_b0350","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s002280000176","article-title":"Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator","volume":"56","author":"DeGregorio","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.steroids.2014.07.012_b0355","doi-asserted-by":"crossref","first-page":"787","DOI":"10.5414\/CP201873","article-title":"Oral bioavailability of ospemifene improves with food intake","volume":"51","author":"Koskimies","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.steroids.2014.07.012_b0360","doi-asserted-by":"crossref","first-page":"861","DOI":"10.5414\/CP201925","article-title":"Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in postmenopausal women","volume":"51","author":"Koskimies","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.steroids.2014.07.012_b0365","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/bdd.1853","article-title":"Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene","volume":"34","author":"Lehtinen","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.steroids.2014.07.012_b0370","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1515\/dmdi-2013-0016","article-title":"Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations","volume":"28","author":"Tolonen","year":"2013","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1016\/j.steroids.2014.07.012_b0375","doi-asserted-by":"crossref","first-page":"14064","DOI":"10.3390\/ijms140714064","article-title":"Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo","volume":"14","author":"Turpeinen","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.steroids.2014.07.012_b0380","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09513590410001672197","article-title":"Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women","volume":"18","author":"Komi","year":"2004","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.steroids.2014.07.012_b0385","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.07.012_b0390","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00774-006-0689-9","article-title":"Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women","volume":"24","author":"Komi","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.steroids.2014.07.012_b0395","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.07.012_b0400","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.maturitas.2014.02.015","article-title":"Ospemifene, a non-estrogen selective oestrogen receptor regulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomized, placebo-controlled, phase III trial","volume":"78","author":"Portman","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.steroids.2014.07.012_b0405","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/gme.0b013e318279ba64","article-title":"Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy","volume":"20","author":"Portman","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.07.012_b0410","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.maturitas.2013.12.005","article-title":"Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women","volume":"77","author":"Simon","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.steroids.2014.07.012_b0415","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.steroids.2014.07.012_b0420","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/13697137.2013.834493","article-title":"Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy","volume":"17","author":"Goldstein","year":"2014","journal-title":"Climacteric"},{"key":"10.1016\/j.steroids.2014.07.012_b0425","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/GME.0b013e318291ef83","article-title":"Postmenopausal dyspareunia: has the Food and Drug Administration really helped?","volume":"20","author":"Goldstein","year":"2013","journal-title":"Menopause"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X14001822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X14001822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T19:17:54Z","timestamp":1717183074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X14001822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":85,"alternative-id":["S0039128X14001822"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2014.07.012","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ospemifene: A first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2014.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}